Tag: MedinCell
Abnormal volumes on today’s session: Medincell, Ose Immunotherapeutics
During this stock market session on Wednesday April 17, 2024, particularly high trading volumes were detected on the French market. Today, it is Medincell stock that stands out, with trading…
Medincell joins forces with AbbVie to develop up to 6 products – 04/17/2024 at 10:15 a.m.
(AOF) – Medincell announced an agreement with the American AbbVie to co-develop and market up to six products in different therapeutic areas and indications. The biotech specialist in long-acting injectable…
Medincell: the stock rises after the agreement concluded with AbbVie – 04/17/2024 at 10:59
(CercleFinance.com) – Medincell shares jumped Wednesday morning on the Paris Stock Exchange after the signing of a strategic agreement with the American AbbVie, known for its flagship drug against rheumatoid…
Medincell will present the strategic co-development and licensing agreement with AbbVie during a webinar on April 17 at 10:00 a.m. CEST – 04/16/2024 at 6:30 p.m.
Strategy, framework of the collaboration, financial terms of the agreement, prospects for Medincell: management invites you to a webinar presenting the co-development and licensing agreement with AbbVie Register by clicking…
Medincell secures new $6M grant from Unitaid
By Alexandra Saintpierre Published on 04/08/2024 at 8:37 p.m. Photo credit © MedinCell (Boursier.com) — The global…
Medincell: Unitaid grant against malaria
(CercleFinance.com) – Medincell indicates that it has received an additional grant of up to six million dollars over three years from the global health agency Unitaid to finance the phase…
Unitaid awards Medincell an additional grant of $6 million to fight malaria – 04/08/2024 at 6:30 p.m.
Global health agency Unitaid has awarded Medincell a top-up grant of up to $6 million over three years to fund the Phase 1 clinical study of the mdc-STM long-acting injectable…
MedinCell will participate in the UBS Virtual CNS Day – 03/15/2024 at 6:00 p.m.
• Christophe Douat, Chairman of the Management Board, and Richard Malamut, Medical Director will present MedinCell’s portfolio of commercial and advanced clinical development products during a virtual conference during the…
Philippe Guy, experienced pharmaceutical industry strategist, becomes Chairman of the supervisory board of MedinCell – 03/13/2024 at 6:30 p.m.
• Philippe Guy led the Healthcare Practice department and served on the executive committee of the Boston Consulting Group (BCG) • He has advised numerous pharmaceutical and biotechnology companies of…
Medincell: Anh Nguyen leaves the presidency of the supervisory board
(AOF) – Anh Nguyen, one of the founders of MedinCell, is leaving his position as member and president of the supervisory board of the biotech specialist in long-acting injectable drugs…
MedinCell – Partner Teva provides 2024 sales forecast for UZEDY™ and provides update on long-acting injectable olanzapine treatment candidate – 01/31/2024 at 10:00 p.m.
· UZEDY revenue forecast for Teva in 2024: ~$80 million · Ongoing phase 3 of Olanzapine LAI: l675 patients (recruitment completed), 62% of 3,600 planned injections completed, no PDSS (post-injection…
MedinCell – Partner Teva announces the end of patient recruitment in the phase 3 clinical study of mdc-TJK, long-acting injectable treatment of olanzapine – 01/09/2024 at 7:20 p.m.
Teva Pharmaceuticals Industries Ltd., announced at the JP Morgan Healthcare Conference that it has successfully completed recruitment in Europe and the United States of the planned 640 participants in the…